Evidence map›Paper›PMID 38796797›Full record

ArticleMolecular diversity2025

An in silico approach to identify novel and potential Akt1 (protein kinase B-alpha) inhibitors as anticancer drugs.

Umadevi Etikyala, Rajkumar Reddyrajula, T Vani, Vinutha Kuchana, Udayakumar Dalimba, Vijjulatha Manga

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Umadevi EtikyalaMedicinal Chemistry Laboratory, Department of Chemistry, Osmania University, Hyderabad, 500076, India.
Rajkumar ReddyrajulaCentral Research Facility, National Institute of Technology Karnataka, Surathkal, Mangalore, 575025, India.
T VaniMedicinal Chemistry Laboratory, Department of Chemistry, Osmania University, Hyderabad, 500076, India.
Vinutha KuchanaMedicinal Chemistry Laboratory, Department of Chemistry, Osmania University, Hyderabad, 500076, India.
Udayakumar DalimbaOrganic Chemistry Laboratory, Department of Chemistry, National Institute of Technology Karnataka, Surathkal, Mangalore, 575025, India.
Vijjulatha MangaMedicinal Chemistry Laboratory, Department of Chemistry, Osmania University, Hyderabad, 500076, India. Vijjulathamanga@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Akt1 (protein kinase B) has become a major focus of attention due to its significant functionality in a variety of cellular processes and the inhibition of Akt1 could lead to a decrease in tumour growth effectively in cancer cells. In the present work, we discovered a set of novel Akt1 inhibitors by using multiple computational techniques, i.e. pharmacophore-based virtual screening, molecular docking, binding free energy calculations, and ADME properties. A five-point pharmacophore hypothesis was implemented and validated with AADRR38. The obtained R

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktComputer SimulationHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingThermodynamicsAntineoplastic AgentsLigandsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktAkt1 inhibitorsBinding free energyMolecular dockingMolecular dynamic simulationPharmacophore-based virtual screeningQSAR model

Identifiers

PMID38796797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.